AustralieFrV1, Main, Exploration, bibRecord, 001940

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Identifieur interne : 001940 ( Main/Exploration ); précédent : 001939; suivant : 001941

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Auteurs : Jeffrey H. Lipton [Canada] ; Charles Chuah [Singapour] ; Agnès Guerci-Bresler [France] ; Gianantonio Rosti [Italie] ; David Simpson [Nouvelle-Zélande] ; Sarit Assouline [Canada] ; Gabriel Etienne [France] ; Franck E. Nicolini [France] ; Philipp Le Coutre [Allemagne] ; Richard E. Clark [Royaume-Uni] ; Leif Stenke [Suède] ; David Andorsky [États-Unis] ; Vivian Oehler [États-Unis] ; Stephanie Lustgarten [États-Unis] ; Victor M. Rivera [États-Unis] ; Timothy Clackson [États-Unis] ; Frank G. Haluska [États-Unis] ; Michele Baccarani [Italie] ; Jorge E. Cortes [États-Unis] ; François Guilhot [France] ; Andreas Hochhaus [Allemagne] ; Timothy Hughes [Australie] ; Hagop M. Kantarjian [États-Unis] ; Neil P. Shah [États-Unis] ; Moshe Talpaz [États-Unis] ; Michael W. Deininger [États-Unis]

Source :

The Lancet. Oncology [ 1474-5488 ] ; 2016.

RBID : pubmed:27083332

Descripteurs français

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions (classification), Drug-Related Side Effects and Adverse Reactions (pathology), Female, Fusion Proteins, bcr-abl (genetics), Humans, Imatinib Mesylate (administration & dosage), Imatinib Mesylate (adverse effects), Imidazoles (administration & dosage), Imidazoles (adverse effects), Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics), Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology), Male, Middle Aged, Philadelphia Chromosome (drug effects), Pyridazines (administration & dosage), Pyridazines (adverse effects), Treatment Outcome.
MESH :
- chemical , administration & dosage : Imatinib Mesylate, Imidazoles, Pyridazines.
- chemical , adverse effects : Imatinib Mesylate, Imidazoles, Pyridazines.
- chemical , genetics : Fusion Proteins, bcr-abl.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- classification : Drug-Related Side Effects and Adverse Reactions.
- drug effects : Philadelphia Chromosome.
- drug therapy : Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- genetics : Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- pathology : Drug-Related Side Effects and Adverse Reactions, Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Treatment Outcome.

Abstract

Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated with arterial occlusion. We investigated whether this activity and safety profile would result in superior outcomes compared with imatinib in previously untreated patients with chronic myeloid leukaemia.

DOI: 10.1016/S1470-2045(16)00080-2
PubMed: 27083332

Affiliations:

Allemagne, Australie, Canada, France, Italie, Nouvelle-Zélande, Royaume-Uni, Singapour, Suède, États-Unis
Aquitaine, Berlin, Californie, Colorado, Grand Est, Lorraine (région), Massachusetts, Michigan, Nouvelle-Aquitaine, Poitou-Charentes, Québec, Svealand, Texas, Utah, Washington (État)
Berlin, Bordeaux, Montréal, Nancy, Poitiers, Stockholm, Vandœuvre-lès-Nancy
Université McGill

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.</title>
<author><name sortKey="Lipton, Jeffrey H" sort="Lipton, Jeffrey H" uniqKey="Lipton J" first="Jeffrey H" last="Lipton">Jeffrey H. Lipton</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: Jeff.Lipton@uhn.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name>
<affiliation wicri:level="1"><nlm:affiliation>Duke-NUS Medical School, Singapore General Hospital, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Duke-NUS Medical School, Singapore General Hospital</wicri:regionArea>
<wicri:noRegion>Singapore General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guerci Bresler, Agnes" sort="Guerci Bresler, Agnes" uniqKey="Guerci Bresler A" first="Agnès" last="Guerci-Bresler">Agnès Guerci-Bresler</name>
<affiliation wicri:level="3"><nlm:affiliation>Brabois Hospital, Vandoeuvre-lès-Nancy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Brabois Hospital, Vandoeuvre-lès-Nancy</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
<settlement type="city">Vandœuvre-lès-Nancy</settlement>
<settlement type="city" wicri:auto="agglo">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Hematology, University of Bologna, Bologna, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Institute of Hematology, University of Bologna, Bologna</wicri:regionArea>
<wicri:noRegion>Bologna</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Simpson, David" sort="Simpson, David" uniqKey="Simpson D" first="David" last="Simpson">David Simpson</name>
<affiliation wicri:level="1"><nlm:affiliation>North Shore Hospital, Westlake, Auckland, New Zealand.</nlm:affiliation>
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>North Shore Hospital, Westlake, Auckland</wicri:regionArea>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Assouline, Sarit" sort="Assouline, Sarit" uniqKey="Assouline S" first="Sarit" last="Assouline">Sarit Assouline</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Oncology, Jewish General Hospital, McGill University, Montréal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Oncology, Jewish General Hospital, McGill University, Montréal, QC</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Etienne, Gabriel" sort="Etienne, Gabriel" uniqKey="Etienne G" first="Gabriel" last="Etienne">Gabriel Etienne</name>
<affiliation wicri:level="3"><nlm:affiliation>Département d'Hématologie, Institut Bergonié, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Département d'Hématologie, Institut Bergonié, Bordeaux</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name>
<affiliation wicri:level="1"><nlm:affiliation>Haematology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Haematology Department, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea>
<wicri:noRegion>Pierre Bénite</wicri:noRegion>
<wicri:noRegion>Pierre Bénite</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Le Coutre, Philipp" sort="Le Coutre, Philipp" uniqKey="Le Coutre P" first="Philipp" last="Le Coutre">Philipp Le Coutre</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clark, Richard E" sort="Clark, Richard E" uniqKey="Clark R" first="Richard E" last="Clark">Richard E. Clark</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal Liverpool University Hospital, Liverpool, Merseyside, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Haematology, Royal Liverpool University Hospital, Liverpool, Merseyside</wicri:regionArea>
<wicri:noRegion>Merseyside</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stenke, Leif" sort="Stenke, Leif" uniqKey="Stenke L" first="Leif" last="Stenke">Leif Stenke</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology-Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Oncology-Pathology, Karolinska Institute and University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andorsky, David" sort="Andorsky, David" uniqKey="Andorsky D" first="David" last="Andorsky">David Andorsky</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Cancer Centers, Boulder, CO, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Cancer Centers, Boulder, CO</wicri:regionArea>
<placeName><region type="state">Colorado</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oehler, Vivian" sort="Oehler, Vivian" uniqKey="Oehler V" first="Vivian" last="Oehler">Vivian Oehler</name>
<affiliation wicri:level="2"><nlm:affiliation>Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Fred Hutchinson Cancer Research Center, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lustgarten, Stephanie" sort="Lustgarten, Stephanie" uniqKey="Lustgarten S" first="Stephanie" last="Lustgarten">Stephanie Lustgarten</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rivera, Victor M" sort="Rivera, Victor M" uniqKey="Rivera V" first="Victor M" last="Rivera">Victor M. Rivera</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clackson, Timothy" sort="Clackson, Timothy" uniqKey="Clackson T" first="Timothy" last="Clackson">Timothy Clackson</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haluska, Frank G" sort="Haluska, Frank G" uniqKey="Haluska F" first="Frank G" last="Haluska">Frank G. Haluska</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, University of Bologna, Bologna, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Hematology and Oncology, University of Bologna, Bologna</wicri:regionArea>
<wicri:noRegion>Bologna</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E" last="Cortes">Jorge E. Cortes</name>
<affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="François" last="Guilhot">François Guilhot</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, Poitiers, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, Poitiers</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
<affiliation wicri:level="1"><nlm:affiliation>Abteilung für Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Abteilung für Hämatologie und Onkologie, Universitätsklinikum Jena, Jena</wicri:regionArea>
<wicri:noRegion>Jena</wicri:noRegion>
<wicri:noRegion>Jena</wicri:noRegion>
<wicri:noRegion>Jena</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name>
<affiliation wicri:level="1"><nlm:affiliation>Haematology Division, Royal Adelaide Hospital, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Haematology Division, Royal Adelaide Hospital, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide</wicri:regionArea>
<wicri:noRegion>Adelaide</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name>
<affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine (Hematology/Oncology), University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine (Hematology/Oncology), University of California, San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Talpaz, Moshe" sort="Talpaz, Moshe" uniqKey="Talpaz M" first="Moshe" last="Talpaz">Moshe Talpaz</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deininger, Michael W" sort="Deininger, Michael W" uniqKey="Deininger M" first="Michael W" last="Deininger">Michael W. Deininger</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT</wicri:regionArea>
<placeName><region type="state">Utah</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27083332</idno>
<idno type="pmid">27083332</idno>
<idno type="doi">10.1016/S1470-2045(16)00080-2</idno>
<idno type="wicri:Area/PubMed/Corpus">001E67</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E67</idno>
<idno type="wicri:Area/PubMed/Curation">001E43</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E43</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001E43</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E43</idno>
<idno type="wicri:Area/Ncbi/Merge">003418</idno>
<idno type="wicri:Area/Ncbi/Curation">003418</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003418</idno>
<idno type="wicri:Area/Main/Merge">001935</idno>
<idno type="wicri:Area/Main/Curation">001940</idno>
<idno type="wicri:Area/Main/Exploration">001940</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.</title>
<author><name sortKey="Lipton, Jeffrey H" sort="Lipton, Jeffrey H" uniqKey="Lipton J" first="Jeffrey H" last="Lipton">Jeffrey H. Lipton</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: Jeff.Lipton@uhn.ca.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name>
<affiliation wicri:level="1"><nlm:affiliation>Duke-NUS Medical School, Singapore General Hospital, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Duke-NUS Medical School, Singapore General Hospital</wicri:regionArea>
<wicri:noRegion>Singapore General Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guerci Bresler, Agnes" sort="Guerci Bresler, Agnes" uniqKey="Guerci Bresler A" first="Agnès" last="Guerci-Bresler">Agnès Guerci-Bresler</name>
<affiliation wicri:level="3"><nlm:affiliation>Brabois Hospital, Vandoeuvre-lès-Nancy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Brabois Hospital, Vandoeuvre-lès-Nancy</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
<settlement type="city">Vandœuvre-lès-Nancy</settlement>
<settlement type="city" wicri:auto="agglo">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Hematology, University of Bologna, Bologna, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Institute of Hematology, University of Bologna, Bologna</wicri:regionArea>
<wicri:noRegion>Bologna</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Simpson, David" sort="Simpson, David" uniqKey="Simpson D" first="David" last="Simpson">David Simpson</name>
<affiliation wicri:level="1"><nlm:affiliation>North Shore Hospital, Westlake, Auckland, New Zealand.</nlm:affiliation>
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>North Shore Hospital, Westlake, Auckland</wicri:regionArea>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Assouline, Sarit" sort="Assouline, Sarit" uniqKey="Assouline S" first="Sarit" last="Assouline">Sarit Assouline</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Oncology, Jewish General Hospital, McGill University, Montréal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Oncology, Jewish General Hospital, McGill University, Montréal, QC</wicri:regionArea>
<orgName type="university">Université McGill</orgName>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Etienne, Gabriel" sort="Etienne, Gabriel" uniqKey="Etienne G" first="Gabriel" last="Etienne">Gabriel Etienne</name>
<affiliation wicri:level="3"><nlm:affiliation>Département d'Hématologie, Institut Bergonié, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Département d'Hématologie, Institut Bergonié, Bordeaux</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name>
<affiliation wicri:level="1"><nlm:affiliation>Haematology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Haematology Department, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea>
<wicri:noRegion>Pierre Bénite</wicri:noRegion>
<wicri:noRegion>Pierre Bénite</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Le Coutre, Philipp" sort="Le Coutre, Philipp" uniqKey="Le Coutre P" first="Philipp" last="Le Coutre">Philipp Le Coutre</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clark, Richard E" sort="Clark, Richard E" uniqKey="Clark R" first="Richard E" last="Clark">Richard E. Clark</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal Liverpool University Hospital, Liverpool, Merseyside, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Haematology, Royal Liverpool University Hospital, Liverpool, Merseyside</wicri:regionArea>
<wicri:noRegion>Merseyside</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stenke, Leif" sort="Stenke, Leif" uniqKey="Stenke L" first="Leif" last="Stenke">Leif Stenke</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology-Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Oncology-Pathology, Karolinska Institute and University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andorsky, David" sort="Andorsky, David" uniqKey="Andorsky D" first="David" last="Andorsky">David Andorsky</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Cancer Centers, Boulder, CO, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Cancer Centers, Boulder, CO</wicri:regionArea>
<placeName><region type="state">Colorado</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oehler, Vivian" sort="Oehler, Vivian" uniqKey="Oehler V" first="Vivian" last="Oehler">Vivian Oehler</name>
<affiliation wicri:level="2"><nlm:affiliation>Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Fred Hutchinson Cancer Research Center, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lustgarten, Stephanie" sort="Lustgarten, Stephanie" uniqKey="Lustgarten S" first="Stephanie" last="Lustgarten">Stephanie Lustgarten</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rivera, Victor M" sort="Rivera, Victor M" uniqKey="Rivera V" first="Victor M" last="Rivera">Victor M. Rivera</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clackson, Timothy" sort="Clackson, Timothy" uniqKey="Clackson T" first="Timothy" last="Clackson">Timothy Clackson</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Haluska, Frank G" sort="Haluska, Frank G" uniqKey="Haluska F" first="Frank G" last="Haluska">Frank G. Haluska</name>
<affiliation wicri:level="2"><nlm:affiliation>ARIAD Pharmaceuticals, Inc, Cambridge, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>ARIAD Pharmaceuticals, Inc, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, University of Bologna, Bologna, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Hematology and Oncology, University of Bologna, Bologna</wicri:regionArea>
<wicri:noRegion>Bologna</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E" last="Cortes">Jorge E. Cortes</name>
<affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="François" last="Guilhot">François Guilhot</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, Poitiers, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM Clinical Investigation Center 1402, Centre Hospitalier et Universitaire de Poitiers, Poitiers</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
<affiliation wicri:level="1"><nlm:affiliation>Abteilung für Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Abteilung für Hämatologie und Onkologie, Universitätsklinikum Jena, Jena</wicri:regionArea>
<wicri:noRegion>Jena</wicri:noRegion>
<wicri:noRegion>Jena</wicri:noRegion>
<wicri:noRegion>Jena</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name>
<affiliation wicri:level="1"><nlm:affiliation>Haematology Division, Royal Adelaide Hospital, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Haematology Division, Royal Adelaide Hospital, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide</wicri:regionArea>
<wicri:noRegion>Adelaide</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name>
<affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine (Hematology/Oncology), University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine (Hematology/Oncology), University of California, San Francisco, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Talpaz, Moshe" sort="Talpaz, Moshe" uniqKey="Talpaz M" first="Moshe" last="Talpaz">Moshe Talpaz</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deininger, Michael W" sort="Deininger, Michael W" uniqKey="Deininger M" first="Michael W" last="Deininger">Michael W. Deininger</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT</wicri:regionArea>
<placeName><region type="state">Utah</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Lancet. Oncology</title>
<idno type="eISSN">1474-5488</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Disease-Free Survival</term>
<term>Drug-Related Side Effects and Adverse Reactions (classification)</term>
<term>Drug-Related Side Effects and Adverse Reactions (pathology)</term>
<term>Female</term>
<term>Fusion Proteins, bcr-abl (genetics)</term>
<term>Humans</term>
<term>Imatinib Mesylate (administration & dosage)</term>
<term>Imatinib Mesylate (adverse effects)</term>
<term>Imidazoles (administration & dosage)</term>
<term>Imidazoles (adverse effects)</term>
<term>Kaplan-Meier Estimate</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics)</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Philadelphia Chromosome (drug effects)</term>
<term>Pyridazines (administration & dosage)</term>
<term>Pyridazines (adverse effects)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Chromosome Philadelphie ()</term>
<term>Effets secondaires indésirables des médicaments ()</term>
<term>Effets secondaires indésirables des médicaments (anatomopathologie)</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Humains</term>
<term>Imidazoles (administration et posologie)</term>
<term>Imidazoles (effets indésirables)</term>
<term>Leucémie myéloïde chronique BCR-ABL positive (anatomopathologie)</term>
<term>Leucémie myéloïde chronique BCR-ABL positive (génétique)</term>
<term>Leucémie myéloïde chronique BCR-ABL positive (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Mésylate d'imatinib (administration et posologie)</term>
<term>Mésylate d'imatinib (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protéines de fusion bcr-abl (génétique)</term>
<term>Pyridazines (administration et posologie)</term>
<term>Pyridazines (effets indésirables)</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Imatinib Mesylate</term>
<term>Imidazoles</term>
<term>Pyridazines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Imatinib Mesylate</term>
<term>Imidazoles</term>
<term>Pyridazines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Fusion Proteins, bcr-abl</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Imidazoles</term>
<term>Mésylate d'imatinib</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Pyridazines</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
<term>Leucémie myéloïde chronique BCR-ABL positive</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Philadelphia Chromosome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Imidazoles</term>
<term>Mésylate d'imatinib</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Pyridazines</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Leucémie myéloïde chronique BCR-ABL positive</term>
<term>Protéines de fusion bcr-abl</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie myéloïde chronique BCR-ABL positive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Chromosome Philadelphie</term>
<term>Effets secondaires indésirables des médicaments</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated with arterial occlusion. We investigated whether this activity and safety profile would result in superior outcomes compared with imatinib in previously untreated patients with chronic myeloid leukaemia.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Nouvelle-Zélande</li>
<li>Royaume-Uni</li>
<li>Singapour</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Aquitaine</li>
<li>Berlin</li>
<li>Californie</li>
<li>Colorado</li>
<li>Grand Est</li>
<li>Lorraine (région)</li>
<li>Massachusetts</li>
<li>Michigan</li>
<li>Nouvelle-Aquitaine</li>
<li>Poitou-Charentes</li>
<li>Québec</li>
<li>Svealand</li>
<li>Texas</li>
<li>Utah</li>
<li>Washington (État)</li>
</region>
<settlement><li>Berlin</li>
<li>Bordeaux</li>
<li>Montréal</li>
<li>Nancy</li>
<li>Poitiers</li>
<li>Stockholm</li>
<li>Vandœuvre-lès-Nancy</li>
</settlement>
<orgName><li>Université McGill</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Lipton, Jeffrey H" sort="Lipton, Jeffrey H" uniqKey="Lipton J" first="Jeffrey H" last="Lipton">Jeffrey H. Lipton</name>
</noRegion>
<name sortKey="Assouline, Sarit" sort="Assouline, Sarit" uniqKey="Assouline S" first="Sarit" last="Assouline">Sarit Assouline</name>
</country>
<country name="Singapour"><noRegion><name sortKey="Chuah, Charles" sort="Chuah, Charles" uniqKey="Chuah C" first="Charles" last="Chuah">Charles Chuah</name>
</noRegion>
</country>
<country name="France"><region name="Grand Est"><name sortKey="Guerci Bresler, Agnes" sort="Guerci Bresler, Agnes" uniqKey="Guerci Bresler A" first="Agnès" last="Guerci-Bresler">Agnès Guerci-Bresler</name>
</region>
<name sortKey="Etienne, Gabriel" sort="Etienne, Gabriel" uniqKey="Etienne G" first="Gabriel" last="Etienne">Gabriel Etienne</name>
<name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="François" last="Guilhot">François Guilhot</name>
<name sortKey="Nicolini, Franck E" sort="Nicolini, Franck E" uniqKey="Nicolini F" first="Franck E" last="Nicolini">Franck E. Nicolini</name>
</country>
<country name="Italie"><noRegion><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name>
</noRegion>
<name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name>
</country>
<country name="Nouvelle-Zélande"><noRegion><name sortKey="Simpson, David" sort="Simpson, David" uniqKey="Simpson D" first="David" last="Simpson">David Simpson</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Berlin"><name sortKey="Le Coutre, Philipp" sort="Le Coutre, Philipp" uniqKey="Le Coutre P" first="Philipp" last="Le Coutre">Philipp Le Coutre</name>
</region>
<name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Clark, Richard E" sort="Clark, Richard E" uniqKey="Clark R" first="Richard E" last="Clark">Richard E. Clark</name>
</noRegion>
</country>
<country name="Suède"><region name="Svealand"><name sortKey="Stenke, Leif" sort="Stenke, Leif" uniqKey="Stenke L" first="Leif" last="Stenke">Leif Stenke</name>
</region>
</country>
<country name="États-Unis"><region name="Colorado"><name sortKey="Andorsky, David" sort="Andorsky, David" uniqKey="Andorsky D" first="David" last="Andorsky">David Andorsky</name>
</region>
<name sortKey="Clackson, Timothy" sort="Clackson, Timothy" uniqKey="Clackson T" first="Timothy" last="Clackson">Timothy Clackson</name>
<name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E" last="Cortes">Jorge E. Cortes</name>
<name sortKey="Deininger, Michael W" sort="Deininger, Michael W" uniqKey="Deininger M" first="Michael W" last="Deininger">Michael W. Deininger</name>
<name sortKey="Haluska, Frank G" sort="Haluska, Frank G" uniqKey="Haluska F" first="Frank G" last="Haluska">Frank G. Haluska</name>
<name sortKey="Kantarjian, Hagop M" sort="Kantarjian, Hagop M" uniqKey="Kantarjian H" first="Hagop M" last="Kantarjian">Hagop M. Kantarjian</name>
<name sortKey="Lustgarten, Stephanie" sort="Lustgarten, Stephanie" uniqKey="Lustgarten S" first="Stephanie" last="Lustgarten">Stephanie Lustgarten</name>
<name sortKey="Oehler, Vivian" sort="Oehler, Vivian" uniqKey="Oehler V" first="Vivian" last="Oehler">Vivian Oehler</name>
<name sortKey="Rivera, Victor M" sort="Rivera, Victor M" uniqKey="Rivera V" first="Victor M" last="Rivera">Victor M. Rivera</name>
<name sortKey="Shah, Neil P" sort="Shah, Neil P" uniqKey="Shah N" first="Neil P" last="Shah">Neil P. Shah</name>
<name sortKey="Talpaz, Moshe" sort="Talpaz, Moshe" uniqKey="Talpaz M" first="Moshe" last="Talpaz">Moshe Talpaz</name>
</country>
<country name="Australie"><noRegion><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001940 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001940 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27083332
   |texte=   Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27083332" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.